Диклак

Quick links to important sections

Диклак

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Диклак

Quick Facts

Property Description
Active ingredient Diclofenac (Sodium/Potassium salt)
Forms Tablet, Solution for injection, Suppository, Gel
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Therapeutic Use Relief of pain, swelling, and inflammation
Origin Synthetic compound (Phenylacetic acid derivative)

What Type of Medicine is Диклак (Diclofenac)?

Диклак (Diclac) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) designed to modulate the body's inflammatory response. The active substance is Diclofenac (INN), which functions as a potent anti-rheumatic agent. Diclofenac is chemically categorized as a synthetic compound, specifically a Phenylacetic acid derivative, confirming its identity within this established pharmacological class. It is pharmacologically recognized that Diclofenac targets the physiological processes that cause both pain and swelling, a dual action that defines its therapeutic role.

Composition and Forms for Versatile Use

The core composition of Диклак involves the single active ingredient, Diclofenac, which is adapted into various dosage forms for distinct routes of administration. Forms include tablets (often enteric-coated), suppositories, solution for injection, and gels, reflecting a versatile therapeutic utility. This variety of forms is a key factor, allowing for delivery via systemic use or through local application. For instance, the gel form is specifically designed to concentrate the active ingredient in the local area, reducing systemic exposure while providing effective analgesia for soft tissue discomfort.

General Therapeutic Purpose of Diclofenac

The general purpose of Диклак is to provide effective symptomatic relief by achieving a distinct anti-inflammatory effect and analgesic effect. The Diclofenac mechanism involves restricting the synthesis of prostaglandins, the chemical messengers that drive pain and swelling in rheumatic diseases and musculoskeletal disorders. This dual-action profile is pharmacologically established and makes it a suitable agent for modulating symptoms in scenarios where pain is directly associated with tissue inflammation.

What side effects are possible with Диклак?

Possible Side Effects and Safety Information

Diclofenac is associated with a risk profile formally documented in regulatory safety labeling, with adverse reactions categorized by frequency and the physiological system affected. The most frequently cited effects are classified as Common, affecting up to 1 in 10 patients, and primarily involve Gastrointestinal Disorders (e.g., nausea, vomiting, diarrhea, abdominal pain) and Nervous System Disorders (e.g., headache, dizziness). These are also linked to changes in liver enzyme levels (transaminases).


Serious Adverse Reactions and Systemic Risks

The official safety information highlights the potential for serious adverse reactions. These include a major risk of Gastrointestinal Bleeding, Ulceration, and Perforation, which is a life-threatening complication documented in regulatory labels. Furthermore, the medicine is associated with a risk of serious Cardiovascular Thrombotic Events, such as myocardial infarction (MI) and stroke.

Other serious, but Rare or Very Rare, effects include severe skin reactions (like Stevens-Johnson syndrome), severe hepatic reactions (e.g., hepatitis, liver failure), and blood disorders.


Safety Patterns and Constraints

The official labeling notes that the risk of serious events, particularly cardiovascular thrombotic events, is associated with long-term use and generally higher doses (e.g., ge 150 mg/day). Safety constraints restrict use in individuals with established conditions such as active gastrointestinal ulcers, bleeding, or perforation, and certain classifications of congestive heart failure (NYHA class II–IV) or ischaemic heart disease. Additionally, older adults are noted to be at a higher risk for serious gastrointestinal complications.

Overdose and Emergency Response

Диклак Overdose and When to Seek Help

Official regulatory documentation states that Diclofenac overdose has the potential for serious and fatal outcomes. Documented manifestations frequently involve the Gastrointestinal system (e.g., nausea, vomiting, stomach pain, bleeding) and the Central Nervous System (e.g., dizziness, drowsiness, confusion, or agitation). High-dose exposure is associated with a greater risk of severe events, including acute renal failure, hepatic failure, and potentially fatal cardiovascular thrombotic events (e.g., myocardial infarction) or GI perforation.

Mandated Emergency Response:

  • Seek medical help right away in case of suspected overdose or over-ingestion, as no specific antidote is known.
  • Immediate medical help is required if severe symptoms manifest, including chest pain, signs of GI bleeding, difficulty breathing, or swelling of the face or throat (anaphylactic reaction).
  • Treatment is symptomatic and supportive care, which may involve procedures like administering activated charcoal and conducting monitoring such as an ECG and blood tests.
  • Official warnings note that elderly patients and those with pre-existing renal or hepatic impairment are at greater risk for severe toxicity in overdose situations.

Therapeutic Uses of Диклак

What Диклак Treats: Main Uses and Benefits

Диклак is commonly used across therapeutic domains where relief from certain distressing symptoms, particularly pain and inflammation, is required. This active ingredient is utilized in managing symptoms linked to inflammatory or irritative states. It is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive.

Key Therapeutic Applications

This medicine is considered relevant for easing symptoms that interfere with daily comfort, such as those arising from musculoskeletal injuries, backache, osteoarthritis, rheumatoid arthritis, and painful menstrual cramps. It is often used during phases when symptoms become more noticeable, providing supportive relief that helps patients cope more steadily. One key benefit is that it assists with maintaining functional stability by managing the associated stiffness and discomfort.

“It is commonly used when short-term symptomatic assistance is needed to address acute or disruptive symptom patterns.”

Quick Fact: Relief for Stiffness

Symptom Management

Диклак is applied in clinical settings that involve acute or unstable symptom patterns. It helps manage the physical manifestations of inflammation, including swelling, heat, and tenderness. This contributes to improved day-to-day comfort, as managing these specific symptoms lessens the overall functional strain caused by the condition.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Eligibility to use Diclofenac (Диклак) is strictly defined by government regulatory documentation, which outlines populations who must not use the medicine and groups requiring conditional use.

Populations for Whom Use is Contraindicated

The medicine is strictly contraindicated and must not be used in the following populations:

  • Patients with known hypersensitivity to the active ingredient, or in whom aspirin/other NSAIDs precipitate asthma, urticaria, or acute rhinitis.
  • Individuals with active gastrointestinal ulceration, bleeding, or perforation, or a history of recurrent peptic ulceration.
  • Patients with established severe congestive heart failure (NYHA II–IV), ischemic heart disease, or those recovering from Coronary Artery Bypass Graft (CABG) surgery.
  • Patients with severe hepatic failure or severe renal failure.
  • Last trimester of pregnancy (use is also generally avoided after 20 weeks gestation).

Age-Related and Conditional Eligibility

Population Group Eligibility Status (Regulatory Basis)
Pediatric (Topical) Contraindicated for those under 14 years (gel formulation).
Geriatric (Older Adults) Use requires caution; lowest effective dose is recommended.
Mild-to-Moderate Impairment Use requires caution and close medical surveillance in mild to moderate hepatic or renal impairment.
Lactation Not recommended for some systemic forms due to lack of experience/unknown excretion into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diclofenac's official interaction profile is defined by pharmacokinetic and pharmacodynamic patterns documented in government regulatory labels.

Type of Interaction Interacting Substances/Context Official Outcome
Pharmacodynamic Risk Anticoagulants (e.g., Warfarin), SSRIs/SNRIs Synergistic increase in the risk of serious bleeding events.
Pharmacokinetic Lithium, Digoxin, Methotrexate Diclofenac reduces the renal clearance of Lithium, causing plasma concentration to elevate. It also increases serum levels and enhances the toxicity of Methotrexate and Digoxin.
Efficacy Modification ACE Inhibitors, ARBs, Diuretics Diclofenac may officially diminish the antihypertensive effect of ACE Inhibitors/ARBs and reduce the natriuretic effect of certain Diuretics.

The co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including low-dose Aspirin, is not generally recommended due to the documented potential for increased adverse effects. A major constraint is the formal contraindication for use in the setting of Coronary Artery Bypass Graft (CABG) surgery. The oral solution formulation requires administration on an empty stomach to prevent a documented reduction in effectiveness from food. Alcohol consumption is officially stated to increase the risk of stomach bleeding. Furthermore, the risk of renal function deterioration with ACE Inhibitors/ARBs is heightened in specific populations, including the elderly or those with existing renal impairment.

Mechanism of Action

The mechanism of Diclofenac involves precisely modulating the physiological pathways that govern inflammation and pain signaling, acting strictly at the molecular and cellular level.


Targeted Enzyme Inhibition and Prostaglandin Modulation

The core mechanism involves the drug acting as a non-selective competitive inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes . This targeted molecular action suppresses the metabolic conversion of Arachidonic Acid, limiting the cellular synthesis and release of pro-inflammatory mediators, primarily Prostaglandins (PGE2). This molecular action limits the downstream physiological effect of excessive mediator activity, defining the core action of the mechanism.


Modulating Peripheral Nociceptive Signaling

The subsequent mechanistic cascade directly modulates the nociceptive signaling pathway. By reducing local prostaglandin concentrations, Diclofenac directly influences the chemical environment surrounding peripheral sensory nerve endings (nociceptors). This mechanism modulates the activity within the nociceptive signaling pathway by limiting the prostaglandin-mediated sensitization of these nerve endings, resulting in a change to the signaling dynamics of the affected physiological pathway.


️ Physiological Constraint: Mechanistic Modulation

The drug operates exclusively within domains that involve physiological modulation. The mechanism engages systems where targeted pathway adjustment is achieved through the inhibition of mediator synthesis; however, it does not alter the underlying chronic pathology or structural defect that initiated the physiological response. This defines the functional boundary of its action.

Dosage and Administration Information

How Диклак is Used: General Administration Guidelines

Diclofenac is utilized via multiple administration routes, including swallowing (oral forms), application to the skin (topical forms), and by injection (parenteral forms). The overarching administrative principle, regardless of the form used, is to adhere to the use of the lowest effective dosage for the shortest duration necessary for symptomatic control.

Systemic oral dosing is structured into divided regimens, typically administered twice or three times daily, to ensure the total daily amount remains below the established maximum dose, which generally ranges from 150 mg to 200 mg per day. The usage protocol for certain oral formulations involves specific conditions: for instance, the powdered oral solution is mixed with 1 to 2 ounces of water and taken on an empty stomach. Conversely, delayed-release tablets may be taken without regard to food, but are swallowed whole and not crushed or chewed.

Topical forms, such as gels or solutions, follow a localized administration schedule, typically applied two or four times daily to the affected area. Parenteral (Intramuscular) injection is generally restricted to an initial, short-term course, often for a maximum of two days, before a transition to oral or rectal administration. For older adults and individuals with mild to moderate renal impairment, no specific dose reduction is typically required for unchanged diclofenac, but cautious adherence to the lowest effective dose is emphasized.

Recent Clinical Evidence

Research evidence / Overview of studies for Диклак

Evidence for use in Chronic Joint Conditions (Osteoarthritis and Rheumatoid Arthritis)

Research has explored the use of Диклак in managing outcomes related to physical discomfort and functional limitations associated with chronic joint conditions, specifically osteoarthritis and rheumatoid arthritis. Studies were conducted during periods of increased symptom activity and monitored patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies related to changes in certain symptoms. Research highlights changes measured during the study period. Studies explored whether use was associated with patterns in these conditions. For osteoarthritis, research examined changes in symptoms, and findings indicate patterns related to temporary changes. For rheumatoid arthritis, studies report how symptoms evolved in the observed populations, and research examined patterns related to observed changes in joint discomfort. Long-term effects on the progression of the underlying conditions are not fully established.

Evidence for use in Acute Pain

Research examined the role of Диклак in conditions associated with acute or disruptive episodes, such as pain following surgery, injury, or severe menstrual pain/migraine. Studies explored short-term symptom changes, focusing on episodes where symptoms become more noticeable, and measured outcomes describing episodic or acute changes.

Studies explored whether short-term use was associated with temporary changes in acute pain. Studies report that patients observed in these research scenarios provided data related to the intensity of their discomfort. Research describes short-term changes and how symptoms evolved in the observed populations during the period immediately following an acute event. These findings describe group patterns, not personal outcomes.

What is still uncertain about Диклак

Evidence highlights what is known—and what is still uncertain—regarding the research on Диклак. Comparative evidence is lacking, and findings were mixed in some areas concerning specific outcomes related to systemic or functional imbalance. Overall, the evidence quality varies across studies. Long-term effects are not fully established for use over many years of intermittent or regular use, and data for certain subgroups remain insufficient, meaning certainty remains low in these contexts.

Key Studies & References

  1. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta‑analysis of randomized, double‑blinded, controlled trials
  2. Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities

Frequently Asked Questions (FAQ)

Common questions about Диклак (FAQ)


Q: Is Диклак considered a strong type of pain reliever?

Regulatory documents classify the active substance in Диклак, Diclofenac, as a potent non-steroidal anti-inflammatory drug (NSAID). This classification indicates the drug is designed to modulate processes related to pain and inflammation. Diclofenac is often included in treatment protocols for conditions associated with moderate to severe pain.


Q: What is the difference between Диклак and other common pain medications like ibuprofen?

Both medicines belong to the NSAID class, and official documents describe Diclofenac as a potent NSAID. However, the official product information also associates Diclofenac with a higher documented risk of certain serious cardiovascular and gastrointestinal complications, especially when used in high doses or for prolonged periods.


Q: Why is Диклак sometimes available as a gel or cream and sometimes as a tablet?

Diclofenac is formulated into different types, such as oral tablets and topical gels, to suit different administration needs. Oral forms are used for systemic treatment—meaning the medicine affects the whole body—while topical forms are applied directly to the skin for localized use to reduce the amount absorbed into the bloodstream.


Q: Are there different types of Диклак products (e.g., immediate release vs. extended release)?

Yes, the active substance is available in various regulated formulations. These include standard (immediate-release), delayed-release (enteric-coated), and extended-release tablets, which are designed to control the timing and duration of the medicine's release into the body.


Q: What is the difference between Диклак and other diclofenac-containing products?

All products containing Diclofenac share the same core active ingredient, fundamental mechanism of action, and overall safety constraints. The differences mainly relate to the specific formulation (such as the salt used or the release mechanism) and the company that markets the product.


Q: What happens in the body when the effects of Диклак wear off?

The effects of the medicine wear off as the active substance is processed and eliminated by the body, mainly through the liver and kidneys. When the drug concentration decreases, the temporary inhibition of pain and inflammation mediators (prostaglandins) begins to reverse.


Q: Is it possible to become reliant on Диклак if used regularly?

No, Diclofenac is a non-steroidal anti-inflammatory drug (NSAID), not a narcotic or a controlled substance. Official regulatory documents indicate that the medicine does not carry a risk of physical dependence or habituation.


Q: Is Диклак suitable for use by older adults, or are there special concerns?

Official information advises that use in older adults requires caution and close medical oversight. This is because this population is at a greater risk for serious side effects, particularly those affecting the stomach, intestines, and kidneys. The principle of using the lowest effective dose for the shortest duration is officially emphasized for this population.


Q: Is Диклак use compatible with breastfeeding?

Official guidance indicates that only very small amounts of the active substance pass into breast milk. Based on current data, Diclofenac is generally considered compatible with breastfeeding.


Q: Can Диклак affect fertility or family planning?

Studies and official information indicate that taking anti-inflammatory medicines like Diclofenac, especially at high doses or for an extended time, may temporarily affect a woman's ability to conceive by interfering with ovulation. Official information advises that if you are trying to become pregnant, the use of the medicine should be considered for interruption.


Q: What should I watch for that might indicate a serious side effect related to the liver or kidney?

While rare, serious effects are noted in official labeling. Liver risks may be indicated by symptoms such as jaundice (yellowing of the skin/eyes), unexplained nausea, or pain in the upper right abdomen. Kidney risks may be indicated by a change in urination patterns, swelling of the limbs, or unusual fatigue.


Q: Is it normal to experience dizziness or drowsiness after taking Диклак?

Dizziness and drowsiness are listed as potential side effects in official product information. The occurrence of these effects is documented in the regulatory safety profile of the medicine.


Q: Can Диклак make skin more sensitive to the sun?

Yes, official safety documents list photosensitivity (increased sensitivity to sunlight) as a potential side effect. This is particularly noted for topical forms of the medicine, and may result in a rash or reaction on sun-exposed skin.


Q: What is the non-directive guidance for using Диклак for period pain (menstrual cramps)?

Certain formulations of Diclofenac are formally approved and indicated in regulatory documents for the relief of pain associated with primary dysmenorrhea (menstrual cramps).


Q: Is Диклак ever used for the relief of migraine headaches?

Yes, official product information confirms that certain formulations of Diclofenac are formally indicated for the acute treatment of migraine attacks, both with and without aura.


Q: Does using Диклак affect how blood clots in the body?

Regulatory documents indicate that Diclofenac has an antiplatelet effect, meaning it influences how blood platelets work to form clots. This effect is why caution is advised when co-administering it with other medicines that affect bleeding.


Q: Can a person take Диклак and acetaminophen (paracetamol) together?

According to official drug interaction profiles, there is no known adverse pharmacokinetic interaction between Diclofenac and acetaminophen (paracetamol). These two substances work differently to relieve pain.


Q: Is it possible to be allergic to Диклак if I have never reacted to ibuprofen?

Official information states that Diclofenac is strictly contraindicated for anyone who has a history of an allergic-type reaction (such as asthma, hives, or rhinitis) to aspirin or other NSAIDs. This is due to the potential for cross-reactivity between different medicines in this class.


Q: What are the signs of a potential allergic reaction to Диклак?

Official safety documents indicate that signs of a serious allergic reaction may include swelling of the face, lips, tongue, or throat, hives, a severe, sudden rash, or difficulty breathing. If such symptoms appear, they should be reviewed by a health professional.


Q: Is Диклак useful for muscle aches that are not related to an inflammatory disease?

Diclofenac is indicated for the relief of pain associated with various musculoskeletal conditions, which includes general muscle aches. Its action is two-fold: it works to modulate inflammation and to relieve pain.


Q: What is the advice for managing mild side effects like wind or bloating while using Диклак?

Mild gastrointestinal effects are documented as common in the product information. The official principle for managing all potential effects is the use of the lowest effective dose for the shortest duration necessary for symptomatic control.


Q: Does official guidance suggest specific monitoring while taking Диклак for a long time?

Yes, official guidance recommends that patients on long-term treatment should receive monitoring. This typically involves checking parameters such as blood pressure, liver function, and kidney function.


Q: Are there known interactions between Диклак and some antidepressant medications?

Yes, official labeling contains warnings about the co-administration of Diclofenac with certain antidepressants, specifically SSRIs and SNRIs. This combination is officially documented to increase the risk of serious gastrointestinal bleeding.


Q: If I have a history of ulcers, can I still use topical forms of Диклак?

Official guidance notes that topical forms of Diclofenac pose a lower systemic risk compared to oral forms, but a history of ulcer disease or gastrointestinal bleeding still warrants caution. The potential risk associated with topical use in those with a history of ulcers must be considered.


Q: Is the risk of side effects higher for people who have diabetes or high blood pressure?

Official labeling advises that patients with certain risk factors, including high blood pressure (hypertension) and diabetes, should use Diclofenac with caution. This is primarily due to the potential for NSAIDs to affect kidney function and blood pressure regulation.


Q: Why is hydration sometimes mentioned in relation to taking NSAIDs like Диклак?

Official regulatory information advises that patients who are dehydrated should have their fluid status corrected before initiating treatment with Diclofenac. This is noted because the medicine can influence kidney function, and regulatory documents advise correction of fluid status to reduce the risk of adverse renal reactions.


Q: Can Диклак be taken if someone is also using a 'water pill' (diuretic)?

Official interaction documents state that Diclofenac can potentially reduce the effectiveness of certain diuretics and, in some cases, increase the risk of kidney injury when taken together. Regulatory documents indicate that this combination warrants cautious use and monitoring.

How should Диклак be stored and disposed of?

How to Store and Dispose of Diclac

Storage of Diclac must adhere strictly to the product's official labeling to maintain its stability and effectiveness. Tablets and suppositories must be stored at temperatures not exceeding 25 C. Certain gel formulations may require storage below 30 C and must be kept in the original container to ensure protection from light. The medicine must, at all times, be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Diclac must be disposed of in accordance with local regulations, as the active substance, diclofenac, is noted to pose a risk to the aquatic environment. The product should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Диклак found in:

A-Z Index: